Session

Unsolved issues in IBD outcome

WHAT IS THE RATE OF DEFINITIVE STOMA AFTER SUBTOTAL COLECTOMY FOR INFLAMMATORY BOWEL DISEASE? A NATIONWIDE STUDY OF 1860 PATIENTS
WHAT IS THE RATE OF DEFINITIVE STOMA AFTER SUBTOTAL COLECTOMY FOR INFLAMMATORY BOWEL DISEASE? A NATIONWIDE STUDY OF 1860 PATIENTS

Unsolved issues in IBD outcome  et al.

IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY
IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY

Unsolved issues in IBD outcome  et al.

REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY
REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY

Unsolved issues in IBD outcome  et al.

IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)
IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)

Unsolved issues in IBD outcome  et al.

IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY
IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY

WHAT IS THE RATE OF DEFINITIVE STOMA AFTER SUBTOTAL COLECTOMY FOR INFLAMMATORY BOWEL DISEASE? A NATIONWIDE STUDY OF 1860 PATIENTS
WHAT IS THE RATE OF DEFINITIVE STOMA AFTER SUBTOTAL COLECTOMY FOR INFLAMMATORY BOWEL DISEASE? A NATIONWIDE STUDY OF 1860 PATIENTS

REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY
REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY

IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)
IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)

Item 1 - 8 / 8
1